Novel approaches to the treatment of sepsis: Lessons learned and future directions

Shock

Volumn 6, Issue 6 SUPPL., 1996, Pages

  Cross, Alan ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

BACTEREMIA; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; PHYSIOLOGY; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BACTEREMIA; CYTOKINES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0029681864     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199610001-00013     Document Type: Article

References (19)

1. Ziegler EJ, McCutchan JA, Fierer J, et al: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230, 1982.
2. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324:429-436, 1991.
3. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102, 1991.
4. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow ED, Shapiro MJ, Greenman RL, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271:1836-1843, 1994.
5. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety on monoclonal antibody to human tumor necrosis factor-x in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter trial. JAMA 273:934-941, 1995.
6. Calandra T, Glauser MP, Schellekens J, Verhoef J, Swiss-Dutch J5 Immunoglobulin Study Group: Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 158:312-319, 1988.
7. Cometta A, Baumgartner J-D, Lee ML, Hanique G, Glauser M-PIVIG Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with core lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234-240, 1992.
8. Schedel I, Dreikhausen U, Nentwig B, et al: Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 19:1104-1113, 1991.
9. Cross AS, Sadoff J, Opal S, Cryz SJ Jr: Immunotherapy of gram-negative bacillary sepsis: a process-oriented approach. In Sande MA, Root RK (eds): Contemptorary Issues in Infectious Diseases: Treatment of Serious Infections in the 1990s, Vol 9. New York, Edinburgh, London, Melbourne, Tokyo: Churchill Livingstone, 1991, pp 77-92.
10. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR, the CHESS Trial Study Group: Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 121:1-5, 1994.
11. 23). J Biol Chem 269:1865-1872, 1994.
12. Von Eschen, KB: Induction of endotoxin tolerance in humans with monophosphoryl lipid A. In Morrison DC, Ryan JL (eds): Novel Therapeutic Strategies in the Treatment of Sepsis. Basel, New York: Marcel Dekker, 1996, pp 149-170.
13. Kawata T, Bristol JR, Rose JR, et al: Specific lipid A analog which exhibits exclusive antagonism of endotoxin. In Morrison DC, Ryan JL (eds): Novel Therapeutic Strategies in the Treatment of Sepsis. Basel, New York: Marcel Dekker, pp 171-186.
14. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 273:934-941, 1995.
15. Fisher CJ Jr, Slotman GJ, Opal SM, et al, and the IL1-ra Sepsis Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of the sepsis syndrome. Crit Care Med 22:12-21, 1994.
16. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P: Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med 169:2021-2027, 1989.
17. Cross A, Asher L, Seguin M, et al: The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli. J Clin Invest 96:676-686, 1995.
18. Opal SM, Palardy J, Parejo N, Jheug J, Cross A: Potential hazards of combination anticytokine therapy in experimental gram-negative sepsis. 35th ICAAC, San Francisco, CA, 1995, abstract B36.
19. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC: The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 167:112-118, 1993.